CN110891972B - 对ror1和cd3的双特异性抗体 - Google Patents

对ror1和cd3的双特异性抗体 Download PDF

Info

Publication number
CN110891972B
CN110891972B CN201880045360.XA CN201880045360A CN110891972B CN 110891972 B CN110891972 B CN 110891972B CN 201880045360 A CN201880045360 A CN 201880045360A CN 110891972 B CN110891972 B CN 110891972B
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880045360.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110891972A (zh
Inventor
阿米特·纳什瓦尼
萨蒂恩·戈希尔
马可·德拉佩鲁塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of CN110891972A publication Critical patent/CN110891972A/zh
Application granted granted Critical
Publication of CN110891972B publication Critical patent/CN110891972B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880045360.XA 2017-07-05 2018-07-05 对ror1和cd3的双特异性抗体 Expired - Fee Related CN110891972B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1710838.2 2017-07-05
GBGB1710838.2A GB201710838D0 (en) 2017-07-05 2017-07-05 Bispecific antibodies
PCT/GB2018/051916 WO2019008379A1 (en) 2017-07-05 2018-07-05 BISPECIFIC ANTIBODIES DIRECTED AGAINST ROR1 AND CD3

Publications (2)

Publication Number Publication Date
CN110891972A CN110891972A (zh) 2020-03-17
CN110891972B true CN110891972B (zh) 2023-05-30

Family

ID=59592717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880045360.XA Expired - Fee Related CN110891972B (zh) 2017-07-05 2018-07-05 对ror1和cd3的双特异性抗体

Country Status (11)

Country Link
US (2) US11306142B2 (enExample)
EP (2) EP3645565B1 (enExample)
JP (1) JP2020529839A (enExample)
CN (1) CN110891972B (enExample)
AU (1) AU2018295479A1 (enExample)
CA (1) CA3068200A1 (enExample)
DK (1) DK3645565T3 (enExample)
ES (1) ES2906361T3 (enExample)
GB (1) GB201710838D0 (enExample)
MX (1) MX2019015349A (enExample)
WO (1) WO2019008379A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
CN111662382A (zh) * 2019-03-06 2020-09-15 瑞阳(苏州)生物科技有限公司 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
KR20220012313A (ko) * 2019-05-23 2022-02-03 벨로스바이오 인코포레이티드 항-ror1/항-cd3 이중특이적 결합 분자
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
TWI841790B (zh) 2019-09-30 2024-05-11 大陸商和鉑醫藥（上海）有限責任公司 靶向cd3的抗體、雙特異性抗體及其用途
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
IL300760A (en) * 2020-08-24 2023-04-01 Epimab Biotherapeutics Hk Ltd Anti-ROR1 antibodies and related bispecific binding proteins
JP7858665B2 (ja) * 2021-02-02 2026-05-14 ヌマブ セラピューティックス アーゲー Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CA3214641A1 (en) * 2021-04-09 2022-10-13 Damien Bresson Oncolytic viruses expressing anti-ror1/anti-cd3 bispecific antibodies
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN118302448A (zh) * 2021-12-28 2024-07-05 江苏恒瑞医药股份有限公司 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途
GB202216284D0 (en) 2022-11-02 2022-12-14 Ucl Business Ltd Self-regulation
WO2024094151A1 (en) * 2022-11-03 2024-05-10 Hansoh Bio Llc Multi-specific antibody and medical use thereof
CN120712345A (zh) * 2022-12-30 2025-09-26 上药生物治疗（香港）有限公司 表达趋化因子受体的细胞及其用途
CN116731178B (zh) * 2023-06-14 2026-07-07 北京大学深圳研究生院 抗人ror1抗体、基因及其应用
WO2025061032A1 (zh) * 2023-09-18 2025-03-27 南京蓬勃生物科技有限公司 靶向人源ror1和cd3的双特异性抗体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429618A (zh) * 2010-12-10 2013-12-04 凯塞若公司 抗ror1抗体及其用途
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CN104662044A (zh) * 2012-08-24 2015-05-27 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
WO2016016344A1 (en) * 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
WO2016055592A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
WO2016115559A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
ATE138106T1 (de) 1988-07-20 1996-06-15 David Segev Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IT1231156B (it) 1989-07-19 1991-11-19 Eniricerche Spa Espressione e secrezione di interleuchina 1 beta umana matura in bacillus subtilis e mezzi e metodi per il suo ottenimento.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
ES2168380T3 (es) 1994-07-15 2002-06-16 Organon Teknika Bv Utilizacion de arn polimerasa para mejorar un procedimiento de amplificacion de acido nucleico.
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7282205B2 (en) 2001-11-07 2007-10-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis A virus antibodies
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
CN101605900B (zh) 2007-01-12 2014-04-23 阿克图杰尼斯公司 乳球菌启动子和其用途
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
US20160017058A1 (en) * 2013-03-14 2016-01-21 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
BR112016000666A2 (pt) * 2013-07-12 2017-10-03 Zymeworks Inc Constructos de ligação de antígeno cd3 e cd19 biespecíficos
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
WO2016016343A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
AU2015313268B2 (en) 2014-09-08 2018-12-20 National Cancer Center Cancer-cell-specific antibody, anticancer agent, and cancer testing method
JP2017536341A (ja) 2014-10-09 2017-12-07 エンクマフ アーゲー 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
EP3253754B1 (en) 2015-02-02 2021-03-31 Kancera AB 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
CN108137669B (zh) 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
HK1253507A1 (zh) 2015-05-18 2019-06-21 Eureka Therapeutics, Inc. 抗 ror1 抗体
CA3001941A1 (en) 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
MX2018008926A (es) 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
CA3011419A1 (en) 2016-01-22 2017-07-27 Janssen Biotech, Inc. Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
US11008318B2 (en) 2016-07-11 2021-05-18 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
US20200338210A1 (en) 2016-12-22 2020-10-29 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
AU2018271872A1 (en) 2017-05-23 2019-12-12 Dragonfly Therapeutics, Inc. A protein binding NKG2D, CD16 and ROR1 or ROR2
TWI804499B (zh) 2017-06-23 2023-06-11 美商維洛斯生物公司 Ror1抗體免疫接合物
EP3645741A4 (en) 2017-06-25 2021-08-25 Systimmune, Inc. ANTI-4-1BB ANTIBODIES AND METHOD OF MANUFACTURING AND USING
US20210139579A1 (en) 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
CN117756946A (zh) 2017-11-03 2024-03-26 莱蒂恩技术公司 用于用抗ror1免疫治疗来治疗癌症的组合物和方法
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429618A (zh) * 2010-12-10 2013-12-04 凯塞若公司 抗ror1抗体及其用途
CN104662044A (zh) * 2012-08-24 2015-05-27 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
WO2016016344A1 (en) * 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
WO2016055592A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
WO2016115559A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1

Also Published As

Publication number Publication date
EP3645565A1 (en) 2020-05-06
JP2020529839A (ja) 2020-10-15
CA3068200A1 (en) 2019-01-10
US11306142B2 (en) 2022-04-19
US20220204621A1 (en) 2022-06-30
AU2018295479A1 (en) 2020-01-16
WO2019008379A1 (en) 2019-01-10
DK3645565T3 (da) 2022-02-14
US20200157218A1 (en) 2020-05-21
EP3645565B1 (en) 2021-12-15
CN110891972A (zh) 2020-03-17
ES2906361T3 (es) 2022-04-18
GB201710838D0 (en) 2017-08-16
EP3985026A1 (en) 2022-04-20
MX2019015349A (es) 2020-07-20

Similar Documents

Publication Publication Date Title
US20220204621A1 (en) Bispecific antibodies to ror1 and cd3
US20250066472A1 (en) Ror1 antibodies
US11723925B2 (en) ROR1 CAR T-cells
AU2022200117B2 (en) Tem8 antibodies and their use
TW201134487A (en) Therapeutic DLL4 binding proteins
CA3087105A1 (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
TW202413422A (zh) 抗體、其抗原結合片段及其藥物用途
HK40071055A (en) Bispecific antibodies to ror1 and cd3
HK40017928B (en) Bispecific antibodies to ror1 and cd3
HK40017928A (en) Bispecific antibodies to ror1 and cd3
KR20220054600A (ko) Il-38-특이적 항체
KR20240004375A (ko) Il-38-특이적 항체
CN117677396A (zh) Il-38特异性抗体
HK40017255B (en) Ror1 car t-cells
HK40017255A (en) Ror1 car t-cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230530